Attention deficit hyperactivity disorder

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Retrieved on: 
Thursday, January 19, 2023
University of California, San Francisco, Ophthalmology, University, CNS, Conference, Patient, ADHD, Research, Phase, USD, Deference, Psychiatry, Attention deficit hyperactivity disorder, Pharmaceutical industry, Medical device

FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the Phase IIa study of its medical treatment, ABV-1505 ADHD, on January 14, 2023 at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.

Key Points: 
  • FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the Phase IIa study of its medical treatment, ABV-1505 ADHD, on January 14, 2023 at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.
  • APSARD is a world-renowned organization consisting of a broad spectrum of allied mental health experts working to improve the quality of care for patients with ADHD through the advancement and dissemination of research, and evidence-based practices.
  • The active pharmaceutical ingredient of ABV-1505, PDC-1421, was used in the Phase IIa study which involved six adult subjects with confirmed ADHD.
  • “We were pleased to have the impressive ABV-1505 ADHD Phase IIa study results presented by Dr. McBurnett at the 2023 APSARD Conference,” said Dr. Howard Doong, Chief Executive Officer of the Company.

XGC Software Inc. Announces Execution of a Non-Binding Letter of Intent to Acquire IntelliGym Labs, an Israeli-Based Leader in Cognitive Enhancement

Retrieved on: 
Thursday, January 5, 2023
Legislation, Israeli Air Force, USA Hockey, Letter, Research, Hockey, IntelliGym, Transaction, Software, Safety, Alzheimer's disease, Therapy, Athlete, US, Attention deficit hyperactivity disorder

This technology platform has been repurposed for cognitive training and enhancement for athletes.

Key Points: 
  • This technology platform has been repurposed for cognitive training and enhancement for athletes.
  • The players then trains their decision-making capabilities, awareness, and anticipation, making meaningful choices with respect to game-time performance.
  • IntelliGym has spent years working with the scientific community testing and researching the benefits of its cognitive training software with a major focus on players’ performance and safety.
  • IntelliGym intends to expand into other sports verticals as well as other verticals that would benefit from IntelliGym’s patented cognitive enhancement technology.

Global Attention Deficit Hyperactivity Disorder Market Report 2022: Increasing Recognition of Behavioral Therapy Benefits Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Neurology, Dextroamphetamine, Electronic health record, Amphetamine, Anxiety, Health, Central nervous system, Bipolar disorder, Clonidine, Depression, Brain, Parent, Narcolepsy, CNS, Johnson & Johnson, Growth, Patient, Attention deficit hyperactivity disorder, Speech, Attention, Movement, ADHD, Attention deficit hyperactivity disorder predominantly inattentive, Guanfacine, Antisocial personality disorder, Pharmacy, SNRI, Laika (EHR testing framework), Methylphenidate, Toy, Pharmaceutical industry

Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.

Key Points: 
  • Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.
  • The stimulants segment procured the highest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • The retail pharmacy segment recorded the largest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • On the basis of region, the attention deficit hyperactivity disorder market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Hyundai-Kia Reveals Details of ZER01NE Creative Platform Promoting Pioneering Startups at CES 2023

Retrieved on: 
Wednesday, January 4, 2023
Cloud, Dementia, ESS, Ecosystem, Lead, VPP, Growth, Attention deficit hyperactivity disorder, Hyundai Motor Group, Investment, ISP, Human, Autol, Virtual power plant, Lidar, Recycling, CES, H/W, Autism, Behavior, Atmosphere, Smart mobility, UX, Wind, Partnership, Original equipment manufacturer, XYZ, 3D, EV, Kia, Hyundai Motor Company, Acquisition, AI, Therapy, Big data, Robotics, Glass, Emotiv, Patient, ADHD, Life, Q&A, 3D printing, Video game, Television, Motor vehicle, Medical device

The ZER01NE Platform highlights Hyundai Motor Group's strategy of building relationships with and nurturing an ecosystem for creators and startups.

Key Points: 
  • The ZER01NE Platform highlights Hyundai Motor Group's strategy of building relationships with and nurturing an ecosystem for creators and startups.
  • "The ZER01NE initiative enables the Group to engage with the best and brightest next-generation startups to develop innovative solutions.
  • The five startups under the ZER01NE Company Builder program exhibiting at the ZER01NE pavilion at CES 2023 are VODA AI, Difon, Fittrix, Wondermove and AutoL.
  • This approach is typified by the latest 10 startups promoted through the ZER01NE Creative Platform at CES 2023 and the pioneering solutions they are developing.

Affinity Foundation Announces New Multi-Year Grant Partners, Committing $360,000 Over the Next Three Years

Retrieved on: 
Wednesday, December 14, 2022
Finance, Banking, Professional Services, Philanthropy, Other Health, Health, Other Philanthropy, Foundation, Other Professional Services, EIN, Nutrition, Rutgers University, Housing, Self-management, St. Louis Fed Financial Stress Index, Substance abuse, Internet, Rutgers Cancer Institute of New Jersey, Conditional sentence, AGAR, Learning, Partnership, Organic, Rutgers School of Communication and Information, Attention deficit hyperactivity disorder, Trustee, Curriculum, Drainage, Knowledge, Employment, Disability in Canada, Diabetes, Woman, Obesity, Homelessness, Education, Barbershop Quartet (health outreach program), Hypertension, Health, Food, Trainer, Student, Organization, Pharmaceutical industry, Hospital, Medicine, Management

The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.

Key Points: 
  • The Affinity Foundation and its Board of Trustees are pleased to announce the launch of the Foundations new multi-year grant program.
  • We are extremely proud to launch this program, said Karla Wallack, Executive Director of the Affinity Foundation.
  • Multi-year grants provide reliable grant revenue that leads to transformational results, and yet they are incredibly hard to find.
  • The Affinity Foundation is a registered nonprofit organization, you can further our mission by donating today (EIN #20-2706810).

ZER01NE, Hyundai-Kia's Creative Talent Platform, to Showcase Innovative Startups at CES 2023

Retrieved on: 
Thursday, December 15, 2022
Hyundai, Attention deficit hyperactivity disorder, Ecosystem, Software, Kia, Accelerator, Acceleration, Hyundai Motor Company, Hyundai Motor Group, Steel, Wind, CES, MVP, Multimedia, Boston Dynamics, Startup accelerator, ADHD, Creative industries, Video game, Motor vehicle, Genesis

At CES 2023, ZER01NE will showcase Hyundai Motor Group's strategy of engaging with and promoting global next-generation startups in the pursuit of innovative solutions to benefit humanity.

Key Points: 
  • At CES 2023, ZER01NE will showcase Hyundai Motor Group's strategy of engaging with and promoting global next-generation startups in the pursuit of innovative solutions to benefit humanity.
  • The ZER01NE Company Builder has fostered 76 in-house startups to date, of which 25 have succeeded in achieving spin-off status.
  • 10 startups will exhibit within the ZER01NE Pavilion at CES 2023, five under the patronage of the ZER01NE Accelerator and five under the banner of the ZER01NE Company Builder.
  • ZER01NE is a Creative Talent Platform that drives open innovation and creates an ecosystem for various creative talents such as artists, architects, designers, engineers, scientists, and entrepreneurs.

Applied Behavior Analysis in Orlando and Winter Garden, Florida Market Report 2022: Global Autism Spectrum Disorder Treatment Market is Expected to Reach $3.17 Billion by 2029

Retrieved on: 
Tuesday, December 6, 2022
Certification, Autism, Attention deficit hyperactivity disorder, BACB, Agency, Oppositional defiant disorder, Fraud, Patient, Applied behavior analysis, ABA, Parent, ODD, Growth, Winter Garden, ASD, ADHD, Insurance, Health insurance, Pharmaceutical industry

DUBLIN, Dec. 6, 2022 /PRNewswire/ --The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 6, 2022 /PRNewswire/ --The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.
  • The Applied Behavior Analysis (ABA) industry is rapidly changing.
  • New opportunities in the form of increased insurance coverage mandates, enhanced technology, and private equity investment place ABA practices in a unique position to capture additional growth.
  • There are 3.5 million children and adults with autism in America.

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

Retrieved on: 
Thursday, December 1, 2022
Anxiety, PTR, Attention, ADHD, Precision Time Protocol, Patient, Attention deficit hyperactivity disorder, CST, Doctor of Pharmacy, Cingulate cortex, Pharmaceutical industry

The appearance had previously been scheduled for Friday December 2, 2022, at 10:00 a.m. CST.

Key Points: 
  • The appearance had previously been scheduled for Friday December 2, 2022, at 10:00 a.m. CST.
  • The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulates PTR platform into the anxiety therapeutic area.
  • The event may be viewed live on Benzingas YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulates website at cingulate.com/investors .
  • Cingulate is headquartered in Kansas City.

Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris's ADHD Portfolio and Pipeline Products in China

Retrieved on: 
Thursday, December 1, 2022
Ketan, Psychology, Allergy, Psychiatry, Attention, CMC, ADHD, Narcolepsy, Risk, Pain, Partnership, Therapy, Physician, Patient, Neurology, Arm, Attention deficit hyperactivity disorder, Neonatology, CNS, Cerebral palsy, Multiple sclerosis, Addiction, FDA, Spasticity, Pharmaceutical industry, Tris

Mr. Zhang Cheng, CEO Pediatrix Therapeutics, added that, "ADHD has serious impact on children's psychology, social functions and family relationships.

Key Points: 
  • Mr. Zhang Cheng, CEO Pediatrix Therapeutics, added that, "ADHD has serious impact on children's psychology, social functions and family relationships.
  • Pediatrix and Tris have reached a strategic collaboration for several novel ADHD products to address patients' unmet needs in China.
  • Pediatrix Therapeutics is a biopharmaceutical company focusing on developing and commercializing high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families in China.
  • Founded in 2021, Pediatrix Therapeutics has built a portfolio of more than 10 products in the therapeutics areas of interest, including psychiatry, neurology, neonatology, allergy and immunology.

2022 Insights on Applied Behavior Analysis in Orlando and Winter Garden, Florida Featuring Market Players Butterfly Effects, Florida Autism Center & Indigo Kids Behavioral Learning - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Alternative Medicine, Health, Growth, ABA, ASD, Winter Garden, ADHD, Certification, Insurance, Patient, Agency, Autism, Applied behavior analysis, Parent, Oppositional defiant disorder, Attention deficit hyperactivity disorder, Fraud, ODD, BACB, Health insurance, Pharmaceutical industry

The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Applied Behavior Analysis in Orlando and Winter Garden, Florida - Market Research Report 2022 " report has been added to ResearchAndMarkets.com's offering.
  • The Applied Behavior Analysis (ABA) industry is rapidly changing.
  • New opportunities in the form of increased insurance coverage mandates, enhanced technology, and private equity investment place ABA practices in a unique position to capture additional growth.
  • There are 3.5 million children and adults with autism in America.